optimizing immunochemistry (IHC) stains and developing multiplexed techniques

KalGene is developing innovative pre-clinical programs in oncology.

Brain cancer

The blood-brain barrier is composed of tightly woven cells that safeguard the brain by repelling harmful agents such as bacteria, while allowing the passage of critical nutrients. Overcoming the barrier is a significant challenge in addressing many diseases affecting the brain; virtually 100% of large molecule medicines are unable to cross the barrier.

By combining their research, the National Research Council of Canada (NRC) and KalGene are targeting glioblastomas, which are severe brain tumours associated with a median patient survival of about 15 months. The collaboration couples KalGene’s proprietary therapeutic with NRC’s single domain antibodies to enable delivery inside the brain, a promising strategy that may lead to improved outcomes for patients. Acting as carriers, NRC’s antibodies will shuttle KalGene’s therapeutic across the challenging blood-brain barrier to target the tumour cells in the brain.

Breast cancer

Worldwide, breast cancer is the most commonly diagnosed cancer among women. KalGene is developing a breast cancer assay to classify breast cancer disease and identify a new subgroup of breast cancer patients who will benefit from specific, tailored therapy regimens. The assay also includes novel molecular targets for the development of new therapies.

Epithelial cancers

Epithelial cancers make up 80-85% of all cancers including breast, bladder, lung, pancreas, thyroid and prostate cancers. KalGene is developing a multi-protein assay to identify aggressive epithelial cancers. The proprietary molecular signature also contains an exciting new drug target for the treatment of several, difficult to treat epithelial cancers.